Inclusion Criteria:  Subjects fully understand and voluntarily participate in this study and sign informed consent; . Age ≥18, female or male; Histologically confirmed diagnosis of head and neck squamous cell carcinoma (including nasopharyngeal carcinoma) Fail to respond to or progressed on at least one line of the standard therapy; At least one measurable lesion according to RECIST v1.1; ECOG performance status of 0 to 1; AEs from the previous treatment have resolved to ≤ Grade 1 based on  Exclusion Criteria:  History of allergy to mitoxantrone hydrochloride or any excipients of the study drug; Untreated or symptomatic central nervous system (CNS) metastases; History of allotransplantation; Life expectancy < 3 months Known hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) or other active viral infection; Serious infection or interstitial pneumonia within 1 week prior to the first dose administration; Use of other anticancer treatment within 4 weeks prior to the first dose administration; Enrolled in any other clinical trials within 4 weeks prior to the first dose administration; Major surgery within 3 months prior to the first dose administration, or have a surgical schedule during the study period; Thrombosis or thromboembolism within 6 months prior to screening; History of, or known additional malignant tumor within 3 years, except for tumors have been cured and have not recurred, and carcinoma in situ; Impaired cardiac function or serious cardiac disease Previous treatment with adriamycin or other anthracyclines, and the total cumulative dose of prior adriamycin or equivalent is >350 mg/m2 Pregnant or lactating female; Serious and/or uncontrolled systemic diseases; Not suitable for this study as decided by the investigator due to other reasons.